Gilles Freyer

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 19

Top Topics

Acute Lymphoblastic Leukemia

Top Venues

Nature communications

Journal of gynecologic oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

JCO clinical cancer informatics

This page only lists publications with an associated author ORCID identifier.

Publications

Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". Journal of gynecologic oncology 35 (3) (2024)
Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". Journal of gynecologic oncology 35 (3) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". Journal of gynecologic oncology (2024)
Pauline Corbaux, Gilles Freyer, Olivier Glehen, Benoit You, Naoual Bakrin, Audrey Gelot, David Dayde, Christophe Sajous, Max Piffoux, Julien Péron, Gaelle Lescuyer, Léa Payen, Vahan Kepenekian
Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Pauline Corbaux, Gilles Freyer, Olivier Glehen, Benoit You, Naoual Bakrin, Audrey Gelot, David Dayde, Christophe Sajous, Max Piffoux, Julien Péron, Gaelle Lescuyer, Léa Payen, Vahan Kepenekian
Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". Journal of gynecologic oncology 35 (3) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Aurore Carrot, Stéphane Oudard, Olivier Colomban, Karim Fizazi, Denis Maillet, A Oliver Sartor, Gilles Freyer, Benoit You
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA. JCO clinical cancer informatics 8 (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". Journal of gynecologic oncology 35 (3) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Aurore Carrot, Stéphane Oudard, Olivier Colomban, Karim Fizazi, Denis Maillet, A Oliver Sartor, Gilles Freyer, Benoit You
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA. JCO clinical cancer informatics 8 (2024)